{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092756","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.999232+00:00","generated_at":"2026-05-31T11:54:13.316270+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tyra Biosciences Q2 net loss $18.7M; cash remains $373.8M; IND cleared for TYRA-430; ACH IND on track","bullets":["Q2 net loss $18.7M ($13.3M in Q2 2023); R&D $18.0M; cash $373.8M, runway through at least 2026.","FDA cleared IND for TYRA-430 (FGFR4/3 biased inhibitor) for Phase 1 in HCC and other solid tumors.","TYRA-300: preclinical proof-of-concept in hypochondroplasia; ACH IND submission on track for 2H24.","CMO Hiroomi Tada to depart by year-end; external search underway; S&T Committee guiding transition.","SURF301 Phase1 initial results for TYRA-300 expected at a scientific congress in 2H24."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092756","json":"https://secwatch.observer/filing/0000950170-24-092756.json","markdown":"https://secwatch.observer/filing/0000950170-24-092756.md","text":"https://secwatch.observer/filing/0000950170-24-092756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024092756/0000950170-24-092756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024092756/tyra-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:54:13.316270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}